Vulnerability to depression鈥塴inked to noradrenaline

News

Vulnerability to depression鈥塴inked to noradrenaline

Published: 15 February 2016

By聽Bruno Geoffroy,聽

First-ever connection between noradrenergic neurons and vulnerability to depression

The team of Bruno Giros, a researcher at the Douglas Mental Health University Institute and professor of psychiatry at 平特五不中, reports the first-ever connection between noradrenergic neurons and vulnerability to depression. Published in the journal Nature Neuroscience, this breakthrough paves the way for new depression treatments that target the adrenergic system.

Stressful life events鈥攋ob loss, accident, death of a loved one鈥攃an trigger major depression in one person, but not in another. A deciding factor is resilience, a biological mechanism that determines an individual鈥檚 capacity to rebound from stressful or traumatic events. Researchers are still learning how resilience works.

鈥淲e know that a small cerebral structure, known as the ventral tegmental area, contains dopaminergic neurons that play a key role in vulnerability to depression,鈥� explains Bruno Giros, whose team is part of the CIUSSS de l鈥橭uest-de-l鈥櫭巐e-de-Montr茅al research network. By mimicking stressful life events in animal models, the researchers confirmed that increased dopaminergic neuron activity corresponds to depression.

Vulnerability under control

Their research further shows that a second type of neuron, noradrenergic neurons, controls dopaminergic neuron activity. 鈥淚t is this control that steers the body鈥檚 response toward resilience or toward vulnerability to depression,鈥� says Giros.

Noradrenergic neurons are located in a cerebral structure named Locus coeruleus. These neurons communicate with each other using noradrenaline, a neurotransmitter molecule involved in emotional regulation, sleep and mood disorders鈥攁nd, Giros now believes, resilience and depression.

By combining pharmacological, genetic and optogenetic (activation of the neurons activity by a light beam) approaches, Giros鈥檚 team showed that animals that cannot release noradrenaline are systematically vulnerable to depression following chronic stress. This is not, however, an irreversible condition: increasing noradrenaline production results in higher resilience鈥攁nd less depression.

鈥淏eyond this discovery about the brain mechanisms involved in depression, our results help explain how adrenergic drugs may work and could be used to treat major depression,鈥� Giros says.

About Bruno Giros

Bruno Giros, PhD, is the holder of the Graham Boeckh Chair in Schizophrenia and the Canada Research Chair in Neurobiology of Mental Disorders. He is one of the world's leading scientists in the study and treatment of schizophrenia. In 1999, he created the Neurobiology and Psychiatry Laboratory at the Institut national de la sant茅 et de la recherche m茅dicale (INSERM) in France. He came to the Douglas Institute in 2008.

About the CIUSSS de l鈥橭uest-de-l鈥櫭巐e-de-Montr茅al

The Centre int茅gr茅 universitaire de sant茅 et de services sociaux (CIUSSS) de l鈥橭uest-de-l鈥櫭巐e-de-Montr茅al is made up of the CSSS de l鈥橭uest-de-l鈥櫭巐e, CSSS de Dorval-Lachine-LaSalle, St. Mary's Hospital, Douglas Mental Health University Institute, West Montreal Readaptation Centre, Grace Dart Extended Care Centre, and Batshaw Youth and Family Centres. It employs 9,000 staff members and 750 physicians.

About the Douglas Mental Health University Institute

The Douglas is a world-class institute affiliated with 平特五不中 and the World Health Organization. It treats people suffering from mental illness and offers them both hope and healing. Its teams of specialists and researchers are constantly increasing scientific knowledge, integrating this knowledge into patient care, and sharing it with the community in order to educate the public and eliminate prejudices surrounding mental health.